Money
Wedbush Adjusts Price Target for Apogee Therapeutics (APGE)
Wedbush has revised its price target for Apogee Therapeutics, reflecting a shift in market expectations and potential implications for infrastructure investment.
Editorial Staff
1 min read
On March 10, 2026, Wedbush announced an increase in the price target for Apogee Therapeutics (APGE). This adjustment signals a positive outlook on the company's market performance.
The revision by Wedbush may influence investor sentiment and strategic decisions regarding Apogee's operational capacity and resource allocation.
As market conditions evolve, stakeholders should consider the implications of this price target change on Apogee's infrastructure and overall market positioning.